TrialCancer communications (London, England)2019

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.

Tianshu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.